Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Opthea Limited

SG&A Expenses: Merck's Stability vs. Opthea's Surge

__timestampMerck & Co., Inc.Opthea Limited
Wednesday, January 1, 2014116060000002652041
Thursday, January 1, 2015103130000002361587
Friday, January 1, 201697620000004472869
Sunday, January 1, 201798300000005030957
Monday, January 1, 2018101020000004988941
Tuesday, January 1, 2019106150000005196412
Wednesday, January 1, 202089550000006652774
Friday, January 1, 2021963400000018418247
Saturday, January 1, 20221004200000024827066
Sunday, January 1, 20231050400000041896408
Monday, January 1, 202415488619
Loading chart...

Data in motion

Navigating SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals, cost management is crucial. Merck & Co., Inc., a titan in the industry, has consistently managed its Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Merck's SG&A expenses have shown a steady trend, peaking in 2014 and 2019, with a slight dip in 2020. This reflects a strategic approach to cost management, maintaining expenses around $10 billion annually.

In contrast, Opthea Limited, a smaller player, has seen a dramatic rise in SG&A expenses, increasing by over 1,500% from 2014 to 2023. This surge, particularly notable in 2023, suggests aggressive expansion and investment in growth. However, data for 2024 is missing, leaving room for speculation on future trends.

This comparison highlights the diverse strategies in managing operational costs within the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025